Immunohistochemical analysis of collagen expression in uterine leiomyomata during the menstrual cycle

Introduction

The extracellular matrix (ECM) is considered to play an crucial role in the stability of tissues and in regulating the growth and differentiation of cells (1,2). Synthesis, accumulation and catabolism of the ECM occur during wound healing and during the initiation and progression of numerous diseases (3).

Moreover, it is generally acknowledged that the ECM does not function as a passive scaffold for connective tissue within the organ architecture, but also plays an ‘informational’ role through a network of interactions between cells and signal molecules. This role is crucial in the control of cellular proliferation and motility during histogenesis for maintenance of tissue homeostasis and in cancer development.

Uterine leiomyomata, or fibroids, are the most common pelvic tumors in women of reproductive age. Despite their prevalence and impact on normal reproductive and menstrual function, little is understood regarding their basic biology and growth. Uterine leiomyoma contains abundant quantities of ECM (4–7). However, the proteins comprising the ECM and the regulation of their expression have yet to be characterized. The study of ECM of uterine leiomyomata and normal myometrium is key in the elucidation of the growth of these neoplasms. Leiomyomata exhibit a low mitotic index, yet undergo rapid growth and, conversely, a rapid decrease in size upon GnRH agonist treatment (8). A significant component of this growth and/or regression may be mediated by changes in the composition and content of the ECM. Therefore, the precise control of ECM metabolism in leiomyomata and normal myometrium is critical for the pathology and development of uterine leiomyomata.

In the present study, the expression of various types of collagen, a major component of ECM, was investigated in human uterine leiomyoma and normal myometrium tissues by immunofluorescent staining. The results were compared to normal myometrium obtained throughout the menstrual cycle.

Materials and methods

This study was approved by the Committee on Investigations Involving Human Subjects of Wakayama Medical College. Informed consent was obtained from each subject after the purpose and nature of the study had been fully explained.

Tissues

Leiomyomata and matched myometrium were processed for immunohistochemistry and SDS-PAGE. The tissues were obtained from 40 pre-menopausal women (29–53 years of age) who were undergoing abdominal hysterectomy for symptomatic uterine leiomyomata at various stages of the menstrual cycle. None of the patients received any hormone therapy prior to surgery. The stage of the menstrual cycle was determined by histological dating of the endometrium for all secretory phase samples. Proliferative phase samples were dated by either dating the endometrium or determining the date of the last menstrual period. The leiomyoma and corresponding myometrium specimens from the proliferative (n=20) and secretory (n=20) phase were studied. No submucosal leiomyomata were collected so as to avoid possible contamination with endometrium. The leiomyomata and myometrium tissues were immediately frozen in liquid nitrogen.

Primary antibodies

Monoclonal antibodies (mAbs) against each α1 chain of human type I, III and IV collagen were used. Preparation of the antibodies has been previously described (9). In brief, BALB/C mice were immunized with each type of collagen, after it had been extracted from human placentas. The spleen cells of the mice were then hybridized with myeloma cells. Following hypoxanthine-aminopterinethymidine (HAT) selection, positive hybrids were identified using an enzyme-linked immunosorbent assay. The specificity of each antibody was determined using immunoblotting or inhibition in an enzyme-linked immunosorbent assay. No cross-reaction was observed among the antibodies.

Immunohistochemistry

Immunohistochemical analysis was performed using the standard indirect immunofluorescence method. In brief, 3-μm frozen sections were rehydrated in phosphate-buffered saline (PBS) at room temperature and then incubated with the primary antibody (diluted 1:100 in PBS) for 12 h at 4°C in a humidified chamber. Following incubation, the sections were washed twice in PBS for 3 min. Each section was then incubated for 1 h at room temperature with human plasma-preabsorbed, fluorescein isothiocyanate-conjugated goat antibodies against mouse immunoglobulins diluted 1:100 in PBS (Organon Teknik, Co., West Chester, PA, USA). Subsequently, the sections were washed again in PBS, mounted in buffered glycerol and examined under a fluorescence microscope (Olympus Co., Tokyo, Japan).

Results

The control sections were stained with goat antibodies against mouse immunoglobulin G without prior application of the appropriate primary antibody (Figs. 1A, 2A and 3A). When the mAbs were first allowed to react with an excess of each specific type of collagen, no immunostaining was observed.

Figure 1. Immunofluorescence micrographs of normal myometrium and leiomyomata with immunostaining by an mAb specific for type I collagen. (A) No immunofluorescence was observed in the control section. Strong immunofluorescence specific for type I collagen is diffusely distributed in the ECM of (C) the leiomyomata as compared to (B) the normal myometrium. The immunostaining of tissues from 19 additional patients yielded similar results (original magnification, ×125).

Figure 2. Immunofluorescence micrographs of normal myometrium and leiomyomata with immunostaining by a monoclonal antibody specific for type III collagen. (A) No immunofluorescence is recognized in the control section. Strong immunofluorescence specific for type III collagen is diffusely distributed in the ECM of (B) the myometrium and (C) the leiomyomata. The immunostaining of tissues from 19 additional patients yielded similar results (original magnification, ×125).

Figure 3. Immunofluorescence micrographs of human myometrium and leiomyoma samples with immunostaining by a monoclonal antibody specific for type IV collagen. (A) No immunofluorescence is recognized in the control section. (B) In normal myometrium, bundles of smooth muscle cells are surrounded by type IV collagen, which is not present in larger septa separating muscle fibers. (C) In the leiomyomata, type IV collagen was localized in bundles of smooth muscle cells, whereas it is absent in areas of ECM accumulation. The immunostaining of tissues from 19 additional patients yielded similar results (original magnification, ×125).

The intensity and distribution of immunohistochemistry for type I, III and IV collagen in the myometrium and leiomyoma samples showed no significant difference between the proliferative and secretory phases, respectively.

Immunostaining with the mAbs against type I and III collagen showed a fibrillary pattern in the ECM of the myometrium and the leiomyomata (Figs. 1B and C and 2B and C). Immunostaining for type I collagen showed an intense and accumulated pattern in much larger areas of the ECM in the leiomyomata as compared to the normal myometrium (Fig. 1B and C). However, immunostaining for type III collagen showed a similarly intense and microfibrillary pattern in the ECM of the leiomyomata and the normal myometrium (Fig. 2B and C).

Immunostaining with the mAbs against type IV collagen showed positive staining of a similar intensity in the myometrium and the leiomyomata (Fig. 3) throughout the menstrual cycle. In the leiomyomata, type IV collagen was localized in the ECM-embedded bundles of smooth muscle cells, whereas areas of ECM accumulation were negative for this collagen (Fig. 3C). Similarly, in the myometrial samples, type IV collagen surrounded smooth muscle cell bundles, but did not contribute to the formation of larger septa separating the muscle fibers. The intensity of staining of the myometrium and leiomyomata by each of the antibodies against various types of collagen was subjectively graded from 1+ to 3+, and the results are summarized in Table I. Although the immunostaining did not allow an accurate quantitative comparison of ECM proteins between the leiomyomata and myometrium, our results suggest that the leiomyomata contained more type I collagen than the normal myometrium due to the larger areas of ECM. There appeared to be no variation in the staining of these collagen types in tissues obtained at different times throughout the menstrual cycle.

Table I. Immunostaining of human uterine myometrium and myoma with antibodies for type I, III and IV collagens.

Table I.

Immunostaining of human uterine myometrium and myoma with antibodies for type I, III and IV collagens.

	No. of patients	Collagen type
		I	III	IV
Myometrium	20	++	++	+
Myoma uteri	20	+++	++	+

[i] Intensities of immunostaining were graded subjectively:

[ii] +, weak staining;

[iii] ++, intense staining;

[iv] +++, very intense staining.

Discussion

In the present study, we investigated changes in the composition of the ECM, including type I, III and IV collagens, in human leiomyomata and normal myometrium tissues obtained throughout the menstrual cycle.

Although type I and III collagens are commonly found in combination, our present study showed that the ratios of type I collagen in the tissues of leiomyomata were significantly higher than those in the normal myometrium throughout the menstrual cycle. However, immunostaining for type III and IV collagen demonstrated a similar pattern in the leiomyomata and the normal myometrium throughout the menstrual cycle. Thus, type I collagen deposition may result in the fibrotic nature of leiomyomata, so called ‘fibroids’. Type I collagen has been demonstrated in the human skin (10) and in human atherosclerosis (11,12). One possible cause is an increase in the density of cells in the leiomyoma tissues.

Cell density-dependent effects have been previously reported in various types of cell, including mesangial (13,14), endothelial (15,16), vascular smooth muscle (17,18), fibroblasts (19,20) and primitive mesenchymal cells (21). It has been suggested that cell density may modulate biological behavior, with changes in signal-transduction responses to hormonal stimulation in growth, in the synthesis and composition of the ECM, and in the synthesis of specific proteins (13,14). Therefore, our findings suggest that leiomyomata exhibit an alteration in cell density or proliferation of their cells and that accumulation of ECM, particularly increased type I collagen in leiomyoma tissues, may play a key role in biological behavior in terms of the reaction to ovarian hormones, such as estrogen and progesterone, as well as cytokines and growth factors, such as TGF-β (22–24).

Moreover, type I collagen has been shown to mediate cell behavior, including attachment, spread, proliferation and morphogenesis (25–28). Therefore, it is suggested that increased relative levels of type I collagen in leiomyomata provide a biochemical basis for the functional regulation of leiomyoma cells as compared to normal myometrium.

In conclusion, an increased level of the protein expression of type I collagen was found in the uterine leiomyomata as compared to that in the normal myometrium throughout the menstrual cycle. Therefore, changes in the composition of collagens, which modulate the expression of various cytokines and growth factors, result in the morphologic and functional characteristics of uterine leiomyomata. This study enhanced the understanding of the pathophysiology of uterine leiomyomata in terms of ECM metabolism. Further research is required to elucidate the mechanisms which regulate the expression of genes of other types of collagen in uterine leiomyomata throughout the menstrual cycle and during hormone therapy.

References